But they're also a natural outgrowth of significant social changes in how we experience disease and death.
Despite this, many patients continue to experience disease recurrence.
However, virtually all glioblastoma patients experience disease progression within 7 to 10 months.
Nearly 90% of patients undergoing imatinib therapy experience disease progression following a significant response despite treatment continuation.
A subset of primarily localized renal cell carcinoma (RCC) patients will experience disease recurrence ≥5 yr after initial nephrectomy.
Here was my chance to address this disparity and bring in those who experience disease as well!
Despite the development of more effective therapies for multiple myeloma (MM) over the past decade, nearly all patients will eventually experience disease relapse and require further therapy.
This new reality is why the Global Fund has prioritized challenging operating environments- countries that experience disease outbreaks, natural disasters, armed conflicts and weak governance.
Although most patients initially respond to cytoreductive surgery and adjuvant paclitaxel and platinum-based chemotherapy, the majority will experience disease recurrence.
However, certain workers positioned close to the brain-removal operation did not experience disease, indicating a potential role for genetic susceptibility or other host factors.
However, approximately 20% of these patients will experience disease recurrence and subsequent death, even if some of them may benefit from adjuvant systemic therapy [6].
